ATP and glutamate are released from separate neurones in the rat medial habenula nucleus: frequency dependence and adenosine-mediated inhibition of release.
1. ATP and glutamatergic synaptic currents were compared in slices of rat medial habenula nucleus using whole-cell patch-clamp techniques. 2. In most cells low voltage stimulation resulted in glutamatergic responses and not purinergic responses. In five cells where ATP currents could be stimulated with low voltages, wash out of glutamate antagonists did not reveal evoked glutamate currents. Spontaneous glutamate currents confirmed washout of antagonist. 3. Modulation of release probability of glutamate and ATP, assessed by changes in failure rate of synaptic currents, was compared under conditions of different stimulation frequencies and in the presence of adenosine agonists and antagonists. 4. ATP release, but not glutamate release, was shown to be modulated by increased stimulation frequency which resulted in inhibition of ATP release via A2-like adenosine receptors. A1 receptors caused inhibition of both ATP and glutamate release. 5. Endogenous adenosine inhibited glutamate release via A1 receptors but only inhibited ATP release via A2-like receptors. 6. Attempts to inhibit the degradation of ATP to adenosine did not alter the frequency dependence of the failure rate. 7. We conclude, from the direct demonstration and from the differences in pharmacology and frequency dependence of the modulation of release, that ATP and glutamate responses are due to release from separate neurones.
Robertson
S J
SJ
Department of Physiology, University College London, Gower Street, London WCIE 6BT, UK. sue.robertson@ucl.ac.uk
Edwards
F A
FA
D018750:6-Cyano-7-nitroquinoxaline-2,3-dione / Q000494:pharmacology; D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000378:metabolism*; D000814:Aniline Compounds / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D019706:Excitatory Postsynaptic Potentials / Q000502:physiology; D005260:Female; D018698:Glutamic Acid / Q000378:metabolism*; D019262:Habenula / Q000166:cytology* / Q000378:metabolism; D008297:Male; D009474:Neurons / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D009708:Nucleotidases / Q000037:antagonists & inhibitors / Q000378:metabolism; D017729:Presynaptic Terminals / Q000737:chemistry / Q000187:drug effects / Q000201:enzymology; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D051381:Rats; D017470:Receptors, Glutamate / Q000502:physiology; D018047:Receptors, Purinergic P1 / Q000502:physiology*; D013498:Suramin / Q000494:pharmacology; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology; D013572:Synaptic Vesicles / Q000737:chemistry / Q000187:drug effects / Q000201:enzymology; D013806:Theophylline / Q000031:analogs & derivatives / Q000494:pharmacology
D000814:Aniline Compounds; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D018691:Excitatory Amino Acid Antagonists; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D017470:Receptors, Glutamate; D018047:Receptors, Purinergic P1; C053907:8-cyclopentyl-1,3-dimethylxanthine; C058394:2-chloro-N(6)cyclopentyladenosine; D018698:Glutamic Acid; D013498:Suramin; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; C050795:N,N-dimethyl-4-anisidine; D000255:Adenosine Triphosphate; D013806:Theophylline; D009708:Nucleotidases; D000241:Adenosine